Reports related to this article:
Project(s): View 5 related projects in PECWeb
Plant(s): View 5 related plants in PECWeb
Released November 23, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Millions of people in the U.S. this week will celebrate Thanksgiving, but there is no such holiday to express gratitude for the generous bounty of pharmaceutical-biotech capital investment across the country. Perhaps there should be, as this bountiful $34 billion cash crop continues to benefit the local population long after the initial harvest, in terms of employment and a boost in-direct income.
Click on the image at right for a graph detailing active Pharmaceutical-Biotech Industry projects in the U.S., by market region.
Drawn from Industrial Info's Pharmaceutical-Biotech Online Database, the $34 billion total investment value (TIV) is divided among 1,445 reported projects. The average project TIV is $23.5 million. The projects are varied as to size and intent, and include both public and privately sourced plans. The one thing that all of the projects have in common is they have yet to begin to construction.
In terms of location, the current leader in planned projects is the Mid-Atlantic region, with a stunning $5.6 billion planned for investment in 154 locations. Helping the region climb into the No. 1 slot is Novo Nordisk AS' (NYSE:NVO) (Bagsvaerd, Denmark) much-ballyhooed $2 billion plan by to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
The Novo Nordisk project is far from the only sizeable investment in the region. Grifols USA (Clayton, North Carolina) has chosen its Clayton site to build a $120 million IVIG Intravenous Immunoglobulin Purification plant. Once operational in 2021, the plant will house IVIG purification production, for therapeutics (including Flebogamma and Gamunex) treating immunodeficiencies and neurological diseases. For more information, see Industrial Info's project reports on the API and IVIG plants.
The West Coast region, long a favorite of the industry, holds slot No. 2 for future kickoffs, claiming 160 projects representing $4.8 billion in planned investment. The largest of the reported projects is a $400 million plan sourced out of the University of California Davis. The school plans to build 300,000-plus square feet of new building space, to serve as a nexus of interdisciplinary research emphasizing the integrative science of chemistry. The Chemistry Discovery Complex will be the campus's largest-ever capital science project. It will consist of a new building and renovations, and additions to the existing Chemistry and Chemistry Annex buildings, as well as Bainer Hall, with construction to occur in phases to completion in 2022. For more information, see Industrial Info's project report.
Rounding out the top three is the Southeast region, with $4.2 billion planned for 208 future projects. In addition to Oak Ridge National Laboratory's (Oak Ridge, Tennessee), there are a number of smaller, yet nevertheless valuable projects through the region. Evonik Corporation (Birmingham, Alabama) has decided to invest in a $27 million expansion of its contract manufacturing (CMO) plant in Birmingham. The project will expand biomaterials production and add a new fill line. For more information, see Industrial Info's project reports on the SNS and CMO plants.
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Millions of people in the U.S. this week will celebrate Thanksgiving, but there is no such holiday to express gratitude for the generous bounty of pharmaceutical-biotech capital investment across the country. Perhaps there should be, as this bountiful $34 billion cash crop continues to benefit the local population long after the initial harvest, in terms of employment and a boost in-direct income.
Click on the image at right for a graph detailing active Pharmaceutical-Biotech Industry projects in the U.S., by market region.
Drawn from Industrial Info's Pharmaceutical-Biotech Online Database, the $34 billion total investment value (TIV) is divided among 1,445 reported projects. The average project TIV is $23.5 million. The projects are varied as to size and intent, and include both public and privately sourced plans. The one thing that all of the projects have in common is they have yet to begin to construction.
In terms of location, the current leader in planned projects is the Mid-Atlantic region, with a stunning $5.6 billion planned for investment in 154 locations. Helping the region climb into the No. 1 slot is Novo Nordisk AS' (NYSE:NVO) (Bagsvaerd, Denmark) much-ballyhooed $2 billion plan by to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
The Novo Nordisk project is far from the only sizeable investment in the region. Grifols USA (Clayton, North Carolina) has chosen its Clayton site to build a $120 million IVIG Intravenous Immunoglobulin Purification plant. Once operational in 2021, the plant will house IVIG purification production, for therapeutics (including Flebogamma and Gamunex) treating immunodeficiencies and neurological diseases. For more information, see Industrial Info's project reports on the API and IVIG plants.
The West Coast region, long a favorite of the industry, holds slot No. 2 for future kickoffs, claiming 160 projects representing $4.8 billion in planned investment. The largest of the reported projects is a $400 million plan sourced out of the University of California Davis. The school plans to build 300,000-plus square feet of new building space, to serve as a nexus of interdisciplinary research emphasizing the integrative science of chemistry. The Chemistry Discovery Complex will be the campus's largest-ever capital science project. It will consist of a new building and renovations, and additions to the existing Chemistry and Chemistry Annex buildings, as well as Bainer Hall, with construction to occur in phases to completion in 2022. For more information, see Industrial Info's project report.
Rounding out the top three is the Southeast region, with $4.2 billion planned for 208 future projects. In addition to Oak Ridge National Laboratory's (Oak Ridge, Tennessee), there are a number of smaller, yet nevertheless valuable projects through the region. Evonik Corporation (Birmingham, Alabama) has decided to invest in a $27 million expansion of its contract manufacturing (CMO) plant in Birmingham. The project will expand biomaterials production and add a new fill line. For more information, see Industrial Info's project reports on the SNS and CMO plants.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Click on the image at right for a graph detailing active Pharmaceutical-Biotech Industry projects in the U.S., by market region.Drawn from Industrial Info's Pharmaceutical-Biotech Online Database, the $34 billion total investment value (TIV) is divided among 1,445 reported projects. The average project TIV is $23.5 million. The projects are varied as to size and intent, and include both public and privately sourced plans. The one thing that all of the projects have in common is they have yet to begin to construction.
In terms of location, the current leader in planned projects is the Mid-Atlantic region, with a stunning $5.6 billion planned for investment in 154 locations. Helping the region climb into the No. 1 slot is Novo Nordisk AS' (NYSE:NVO) (Bagsvaerd, Denmark) much-ballyhooed $2 billion plan by to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
The Novo Nordisk project is far from the only sizeable investment in the region. Grifols USA (Clayton, North Carolina) has chosen its Clayton site to build a $120 million IVIG Intravenous Immunoglobulin Purification plant. Once operational in 2021, the plant will house IVIG purification production, for therapeutics (including Flebogamma and Gamunex) treating immunodeficiencies and neurological diseases. For more information, see Industrial Info's project reports on the API and IVIG plants.
The West Coast region, long a favorite of the industry, holds slot No. 2 for future kickoffs, claiming 160 projects representing $4.8 billion in planned investment. The largest of the reported projects is a $400 million plan sourced out of the University of California Davis. The school plans to build 300,000-plus square feet of new building space, to serve as a nexus of interdisciplinary research emphasizing the integrative science of chemistry. The Chemistry Discovery Complex will be the campus's largest-ever capital science project. It will consist of a new building and renovations, and additions to the existing Chemistry and Chemistry Annex buildings, as well as Bainer Hall, with construction to occur in phases to completion in 2022. For more information, see Industrial Info's project report.
Rounding out the top three is the Southeast region, with $4.2 billion planned for 208 future projects. In addition to Oak Ridge National Laboratory's (Oak Ridge, Tennessee)
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Millions of people in the U.S. this week will celebrate Thanksgiving, but there is no such holiday to express gratitude for the generous bounty of pharmaceutical-biotech capital investment across the country. Perhaps there should be, as this bountiful $34 billion cash crop continues to benefit the local population long after the initial harvest, in terms of employment and a boost in-direct income.
Click on the image at right for a graph detailing active Pharmaceutical-Biotech Industry projects in the U.S., by market region.
Drawn from Industrial Info's Pharmaceutical-Biotech Online Database, the $34 billion total investment value (TIV) is divided among 1,445 reported projects. The average project TIV is $23.5 million. The projects are varied as to size and intent, and include both public and privately sourced plans. The one thing that all of the projects have in common is they have yet to begin to construction.
In terms of location, the current leader in planned projects is the Mid-Atlantic region, with a stunning $5.6 billion planned for investment in 154 locations. Helping the region climb into the No. 1 slot is Novo Nordisk AS' (NYSE:NVO) (Bagsvaerd, Denmark) much-ballyhooed $2 billion plan by to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
The Novo Nordisk project is far from the only sizeable investment in the region. Grifols USA (Clayton, North Carolina) has chosen its Clayton site to build a $120 million IVIG Intravenous Immunoglobulin Purification plant. Once operational in 2021, the plant will house IVIG purification production, for therapeutics (including Flebogamma and Gamunex) treating immunodeficiencies and neurological diseases. For more information, see Industrial Info's project reports on the API and IVIG plants.
The West Coast region, long a favorite of the industry, holds slot No. 2 for future kickoffs, claiming 160 projects representing $4.8 billion in planned investment. The largest of the reported projects is a $400 million plan sourced out of the University of California Davis. The school plans to build 300,000-plus square feet of new building space, to serve as a nexus of interdisciplinary research emphasizing the integrative science of chemistry. The Chemistry Discovery Complex will be the campus's largest-ever capital science project. It will consist of a new building and renovations, and additions to the existing Chemistry and Chemistry Annex buildings, as well as Bainer Hall, with construction to occur in phases to completion in 2022. For more information, see Industrial Info's project report.
Rounding out the top three is the Southeast region, with $4.2 billion planned for 208 future projects. In addition to Oak Ridge National Laboratory's (Oak Ridge, Tennessee)
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
